Wang et al. carried out a prospective phase II trial to evaluate the efficacy and safety of anti-EGFR monoclonal antibody combined with intensity-modulated radiation therapy in locally advanced oropharyngeal carcinoma (NCT04508829). Here, EGFR is linked to oropharyngeal carcinoma.